Rare cannabinoids that cannot practically be extracted from hemp will instead be manufactured by specially-created micro-organisms.
A new partnership between Cronos Group, a Canadian vertically integrated cannabis company, and Ginkgo Bioworks, a Massachusetts-based bioengineering specialist, will see Ginkgo modify the DNA of yeast so that it can produce cannabinoids in a fermentation process.
They include cannabidiolic acid (CBDA), a substance naturally present in the hemp plant, which is then turned into cannabidiol (CBD) when its chemical composition is altered through heating.
Get access to premium content that is normally only available for subscribers. For the duration of a week, you can read our news analysis, identify market trends and understand upcoming changes in the industry, which will enable you to get ahead of your competitors.